|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 2047 |
FusionGeneSummary for AP2A1_DHDH |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: AP2A1_DHDH | Fusion gene ID: 2047 | Hgene | Tgene | Gene symbol | AP2A1 | DHDH | Gene ID | 160 | 27294 |
| Gene name | adaptor related protein complex 2 subunit alpha 1 | dihydrodiol dehydrogenase | |
| Synonyms | ADTAA|AP2-ALPHA|CLAPA1 | 2DD|HUM2DD | |
| Cytomap | 19q13.33 | 19q13.33 | |
| Type of gene | protein-coding | protein-coding | |
| Description | AP-2 complex subunit alpha-1100 kDa coated vesicle protein Aadapter-related protein complex 2 alpha-1 subunitadapter-related protein complex 2 subunit alpha-1adaptin, alpha Aadaptor protein complex AP-2 subunit alpha-1adaptor related protein complex | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase3-deoxyglucosone reductaseD-xylose 1-dehydrogenaseD-xylose-NADP dehydrogenasedihydrodiol dehydrogenase (dimeric) | |
| Modification date | 20180522 | 20180523 | |
| UniProtAcc | O95782 | Q9UQ10 | |
| Ensembl transtripts involved in fusion gene | ENST00000354293, ENST00000600199, ENST00000359032, | ENST00000221403, ENST00000523250, ENST00000522614, | |
| Fusion gene scores | * DoF score | 6 X 7 X 6=252 | 3 X 2 X 2=12 |
| # samples | 7 | 3 | |
| ** MAII score | log2(7/252*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/12*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: AP2A1 [Title/Abstract] AND DHDH [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | AP2A1 | GO:1900126 | negative regulation of hyaluronan biosynthetic process | 24251095 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | BRCA | TCGA-A2-A25D-01A | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000354293 | ENST00000221403 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 5CDS-intron | ENST00000354293 | ENST00000523250 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 5CDS-intron | ENST00000354293 | ENST00000522614 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 3UTR-3CDS | ENST00000600199 | ENST00000221403 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 3UTR-intron | ENST00000600199 | ENST00000523250 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 3UTR-intron | ENST00000600199 | ENST00000522614 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| Frame-shift | ENST00000359032 | ENST00000221403 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 5CDS-intron | ENST00000359032 | ENST00000523250 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
| 5CDS-intron | ENST00000359032 | ENST00000522614 | AP2A1 | chr19 | 50270457 | + | DHDH | chr19 | 49442706 | + |
Top |
FusionProtFeatures for AP2A1_DHDH |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| AP2A1 | DHDH |
| Component of the adaptor protein complex 2 (AP-2).Adaptor protein complexes function in protein transport viatransport vesicles in different membrane traffic pathways. Adaptorprotein complexes are vesicle coat components and appear to beinvolved in cargo selection and vesicle formation. AP-2 isinvolved in clathrin-dependent endocytosis in which cargo proteinsare incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with theearly endosome. The clathrin lattice serves as a mechanicalscaffold but is itself unable to bind directly to membranecomponents. Clathrin-associated adaptor protein (AP) complexeswhich can bind directly to both the clathrin lattice and to thelipid and protein components of membranes are considered to be themajor clathrin adaptors contributing the CCV formation. AP-2 alsoserves as a cargo receptor to selectively sort the membraneproteins involved in receptor-mediated endocytosis. AP-2 seems toplay a role in the recycling of synaptic vesicle membranes fromthe presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi)and [ED]-X-X-X-L-[LI] endocytosis signal motifs within thecytosolic tails of transmembrane cargo molecules. AP-2 may alsoplay a role in maintaining normal post-endocytic traffickingthrough the ARF6-regulated, non-clathrin pathway. The AP-2 alphasubunit binds polyphosphoinositide-containing lipids, positioningAP-2 on the membrane. The AP-2 alpha subunit acts via its C-terminal appendage domain as a scaffolding platform for endocyticaccessory proteins. The AP-2 alpha and AP-2 sigma subunits arethought to contribute to the recognition of the [ED]-X-X-X-L-[LI]motif (By similarity). {ECO:0000250, ECO:0000269|PubMed:14745134,ECO:0000269|PubMed:15473838, ECO:0000269|PubMed:19033387}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for AP2A1_DHDH |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for AP2A1_DHDH |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| AP2A1 | DPYSL2, NUMB, L1CAM, CD22, EHD1, NAGPA, EPS15, CLINT1, RAB11FIP2, ARRB2, BRCA1, SHBG, RALBP1, REPS2, EPN1, AMPH, SYNJ1, GRK5, ABL1, SHC1, CRK, AP2M1, MYO6, AP2A2, PICALM, FN1, VCAM1, DAB2, SMAD9, ITGA4, MMS19, ARRB1, RNF11, EGFR, GRB2, PPP6R3, PIN1, BIN1, RPA3, RPA2, RPA1, ABCB11, EPHA2, OBSL1, AAK1, SLC25A41, NECAP2, LRFN4, AAGAB, ZBTB46, SPC25, NTRK1, AP1B1, AP2S1, NUTF2, AP2B1, EIF2B1, MED4, MED23, CEP128, XPO1, CAPZA2, CLTB, CLTC, DBN1, FLNA, GAK, MYH9, PPP1CB, PPP1CC, IQGAP1, PDLIM7, SEC16A, SYNPO, LIMA1, GTSE1, ANLN, MYO5C, MYO19, ARX, MYO18A, CFAP97, MCM2, MEX3C, FBXW7, DIEXF, ZNF746, ARFGAP1, SNX9, RUNDC3A, GPR156, GPBP1L1, FCHO1, INTS4, OCRL, SOST, STAMBP, REPS1, PPP6R2, LSR, C11orf57, GJB7, UBC, ARF6, TRIM25 | DHDH | CCDC12, TSC22D1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for AP2A1_DHDH |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for AP2A1_DHDH |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | DHDH | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|